Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.

Of note, in the low-medium tau burden group, the high-dose group performed worse on the primary endpoint, whereas the low-dose group showed a trend towards improvement compared with the placebo group.

also in 53,322 other papers